Ann: Change in substantial holding, page-5

First 5 Last

Share
Profile

Follow
tinhat

5,681 Posts.

1742

02/08/21

18:49

Post #: 54972313
Share

Originally posted by MarkinaSasha: ↑

kurt is the man, he has so much experience in company growth.

he deserves these reward shares.

Overseeing growth and successful sales of 4 separate entities for investors, Mueffelmann draws on over 25 years of experience in helping high-tech companies reach their full potential through internal growth and strategic combinations. As CEO, he led two separate companies, including HiSoftware and Create!Form to being named to Deloitte Technology Fast 500 list which recognizes the fastest growing technology companies.

Mueffelmann was previously CEO of Cryptzone and HiSoftware; where he oversaw the sale to a private equity firm, restructured into a US-based entity, drove the combination and growth of the entities across 4 continents through an expanded distribution channel of high-velocity, enterprise and channel sales, as well as raised a Series B round of funding for $15m.

Previously, Kurt was Sr. Vice President and General Manager of $50m in revenue for both the Document Output Solutions and Business Process Solutions lines of business at Bottomline Technologies (NASDAQ: EPAY); which acquired one of his other firms Create!form International. He has also served as President and Chief Executive Officer of RealWorld Corporation, where he oversaw successful acquisitions by Great Plains Software, now part of Microsoft.

this is a man you want at the helm

Expand

He deserves those shares just because of his name. How can you argue with Kurt Mueffelmann?

AR9 Price at posting: 37.0¢ Sentiment: None Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 4 more messages in this thread...

First 5 Last

Add AR9 (ASX) to my watchlist

(20min delay)
Last 8.3¢		Change -0.001(1.19%)		Mkt cap ! $23.78M

Open	High	Low	Value	Volume
8.5¢	8.5¢	8.3¢	$21.17K	251.8K

Buyers (Bids)

No.	Vol.	Price($)
2	22440	8.3¢

Sellers (Offers)

Price($)	Vol.	No.
8.5¢	50746	2

View Market Depth

No.	Vol.	Price($)
2	22440	0.083
1	6109	0.082
1	30000	0.080
1	6333	0.079
2	42026	0.078

Price($)	Vol.	No.
0.085	50746	2
0.086	43700	3
0.087	93351	1
0.088	6239	1
0.089	610	1

Last trade - 15.46pm 07/10/2024 (20 minute delay)

AR9 (ASX) Chart

Ann: Change in substantial holding, page-5

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Change in substantial holding, page-5

Top Stories

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News